Analogs of the Cathelicidin-Derived Antimicrobial Peptide PMAP-23 Exhibit Improved Stability and Antibacterial Activity

Yongqing Liu,Tengfei Shen,Liangliang Chen,Jiangfei Zhou,Chen Wang

DOI: https://doi.org/10.1007/s12602-020-09686-z

2020-07-14

Probiotics and Antimicrobial Proteins

Abstract:Antimicrobial peptides (AMPs) have gained interesting as a new type of antimicrobial agent. The cathelicidin-derived antimicrobial peptide PMAP-23 has broad-spectrum antibacterial activity, and to improve its antimicrobial activity, we used amino acid substitution at position 5 or 19 of PMAP-23 to design three analogs, named PMAP-23R (Leu⁵--Arg), PMAP-23I (Thr¹⁹--Ile), and PMAP-23RI (Leu⁵--Arg and Thr¹⁹--Ile). We found that the analog peptides exhibited higher stability and improved antibacterial activity compared with PMAP-23. Additionally, the analog peptides PMAP-23I and PMAP-23RI inhibited the growth of <i>Shigella flexneri</i> CICC 21534, whereas PMAP-23 and PMAP-23R exhibited no antibacterial activity against <i>S. flexneri</i> CICC 21534. Moreover, the peptide analogs showed negligible hemolysis and cytotoxicity. We also found that PMAP-23RI exerted impressive therapeutic effects on mice infected with <i>Staphylococcus aureus</i> ATCC 25923 and <i>Salmonella enterica</i> serovar Typhimurium SL1344. PMAP-23RI induced a greater reduction in pathological damage and a higher decrease in the bacterial gene copies in the lung and liver tissues and greatly reduced mouse mortality. In conclusion, the peptide analogs PMAP-23R, PMAP-23I, and PMAP-23RI enhanced the stability and antimicrobial activity of PMAP-23, but PMAP-23RI exhibits more promise as a new antimicrobial agent candidate for the treatment of bacterial infections.

biotechnology & applied microbiology,microbiology